U.S. Markets close in 3 hrs 37 mins

ARIAD at H.C upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright assumed coverage on ARIAD with a Buy rating from a Neutral rating based on expected Iclusig share gains and the lifting of partial clinical holds allowing investigators to look at new indications. Price target is $14.